Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 395

Results For "EU"

5414 News Found

AeroSafe Global appointment Jessica Cao as Sr VP (Marketing)
People | June 11, 2022

AeroSafe Global appointment Jessica Cao as Sr VP (Marketing)

Company hires life science veteran Jessica Cao to join management team


Marinus expands enrollment criteria to support recruitment in Phase 3 RAISE Trial in refractory status epilepticus
Clinical Trials | June 10, 2022

Marinus expands enrollment criteria to support recruitment in Phase 3 RAISE Trial in refractory status epilepticus

Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.


Olema Oncology and Aurigene collaboration to discover and develop novel cancer therapies
News | June 10, 2022

Olema Oncology and Aurigene collaboration to discover and develop novel cancer therapies

During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.


Sanofi Dupixent gets USFDA nod for atopic dermatitis
Drug Approval | June 10, 2022

Sanofi Dupixent gets USFDA nod for atopic dermatitis

Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood


GE Healthcare’s molecular imaging solutions enable precision health & theranostics for prostate cancer
News | June 10, 2022

GE Healthcare’s molecular imaging solutions enable precision health & theranostics for prostate cancer

Healthcare is timely and personal – and its delivery should be too


Bayer’s Vividion emerging as significant player in San Diego Biotech hub
Biotech | June 10, 2022

Bayer’s Vividion emerging as significant player in San Diego Biotech hub

Bayer now present in four of the largest biotechnology hubs in the United States


Sumitomo Pharma Oncology receives orphan drug designation for the treatment of myelofibrosis
Drug Approval | June 09, 2022

Sumitomo Pharma Oncology receives orphan drug designation for the treatment of myelofibrosis

TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.


Prolacta Bioscience appoints David Steinberg as CFO
People | June 08, 2022

Prolacta Bioscience appoints David Steinberg as CFO

Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.


Merck and Ridgeback announce new data for investigational molnupiravir
News | June 08, 2022

Merck and Ridgeback announce new data for investigational molnupiravir

Based on a post hoc analysis, fewer required respiratory interventions


Novartis Tafinlar and Mekinist demonstrates unprecedented efficacy in pediatric patients
News | June 08, 2022

Novartis Tafinlar and Mekinist demonstrates unprecedented efficacy in pediatric patients

If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer